Compare Repligen Corporation Common Stock (RGEN) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TotalEnergies SE — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while TotalEnergies SE trades at $90.93 (market cap $197.99B). The key difference: TotalEnergies SE is far larger — about 17.5× Repligen Corporation Common Stock's market cap, and TotalEnergies SE pays a 4.73% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TotalEnergies SE for 91 Days on average.
| RGEN | TTE | |
|---|---|---|
Market Cap | $11.31B | $197.99B |
Volume | 1,216,919 | 2,678,834 |
Sector | Health | Energy |
52-Week High | $194.57 | $93.60 |
52-Week Low | $102.87 | $60.44 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $11.20B | $228.98B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TotalEnergies (TTE) trades at $88.95, up 0.66% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a P/E of 11.13 and ROE of 14.56%, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent news highlights a $10B investment in Argentina and a $2.5B Q4 buyback increase, signaling aggressive growth plans.
Outlook remains positive with a consensus price target of $95.33, but risks include volatile oil prices and execution of expansion strategies. The company's focus on LNG and power diversification, coupled with a 5% dividend growth target by 2030, offers a balanced opportunity for value investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
